Characterization of volume-sensitive taurine- and Cl(-)-permeable channels.
Volume-sensitive Cl- channels [ICl(vol)] were studied using taurine efflux and patch-clamp experiments in 9HTEo- human tracheal cells. Cells were stimulated with the Ca(2+)- elevating agents ATP and ionomycin in isotonic medium or in hypotonic solutions. ATP (100 microM) or ionomycin (1 microM) and hypotonic shock produced a synergic effect. Indeed, the resulting taurine efflux was much higher than the sum of the single effects elicited by ATP, ionomycin, or hypotonic medium. The taurine release elicited by hypotonic shock and the potentiation by ATP and ionomycin were markedly inhibited by using a Ca(2+)-free extracellular medium and by incubating the cells with the membrane-permeable 1,2-bis(2-amino- phenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester chelating agent. Patch-clamp experiments confirmed the role of Ca2+ on ICl(vol) channels. Swelling-induced taurine efflux was inhibited by reactive blue 2, suramin, and pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid. Patch-clamp experiments demonstrated that these compounds shift the voltage-dependent inactivation of ICl(vol) channels toward more negative values. This study indicates that the sensitivity of ICl(vol) to cell volume changes is modulated by intracellular Ca2+ and that purinergic receptor antagonists represent a new class of CI- channel blockers.
Galietta
L J
LJ
Lab di Genetica Molecolare, Istituto Giannina Gaslini, Genoa, Italy.
Falzoni
S
S
Di Virgilio
F
F
Romeo
G
G
Zegarra-Moran
O
O
D000255:Adenosine Triphosphate / Q000378:metabolism / Q000494:pharmacology; D000957:Antigens, Viral, Tumor / Q000096:biosynthesis; D002118:Calcium / Q000378:metabolism; D002461:Cell Line, Transformed; D002614:Chelating Agents / Q000494:pharmacology; D018118:Chloride Channels / Q000187:drug effects / Q000502:physiology*; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004848:Epithelium / Q000502:physiology; D006801:Humans; D007038:Hypotonic Solutions; D015759:Ionomycin / Q000494:pharmacology; D007700:Kinetics; D008564:Membrane Potentials / Q000187:drug effects; D018408:Patch-Clamp Techniques; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D013539:Simian virus 40; D013498:Suramin / Q000494:pharmacology; D013654:Taurine / Q000378:metabolism*; D014132:Trachea; D014227:Triazines / Q000494:pharmacology
D000957:Antigens, Viral, Tumor; D002614:Chelating Agents; D018118:Chloride Channels; D004791:Enzyme Inhibitors; D007038:Hypotonic Solutions; D014227:Triazines; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D013654:Taurine; D004533:Egtazic Acid; D015759:Ionomycin; C012842:Cibacron Blue F 3GA; D011732:Pyridoxal Phosphate; D013498:Suramin; D000255:Adenosine Triphosphate; C025603:1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; D002118:Calcium